23:45 , Jun 19, 2019 |  BC Extra  |  Clinical News

June 19 Clinical Quick Takes: G1 jumps on breast cancer data; plus Linzess, Lokelma, Boehringer/OSE, GCAR and more

G1 rises on trilaciclib OS efficacy in Phase II for TNBC  G1 Therapeutics Inc. (NASDAQ:GTHX) has gained 33% to $26.27 since reporting preliminary data Tuesday from a Phase II trial showing a statistically significant improvement...
00:36 , Jun 8, 2019 |  BioCentury  |  Product Development

ASCO 2019 sessions provide guidance on expanding patient pools for clinical trials

Two sessions at this year's American Society of Clinical Oncology meeting gave drug developers a glimpse of how to match more patients to clinical trials by broadening eligibility criteria and encouraging trial enrollment in community...
00:12 , Jun 4, 2019 |  BC Innovations  |  Distillery Therapeutics

Otsuka's mitochondrial uncoupler for metabolic, cardiovascular indications

DISEASE CATEGORY: Endocrine/metabolic; cardiovascular INDICATION: Diabetes; metabolic syndrome; stroke; hypertension Rat and mouse studies suggest the mitochondrial uncoupler OPC-163493 could help treat Type I and Type II diabetes, metabolic syndrome, stroke and hypertension. In three...
23:20 , Jun 3, 2019 |  BC Extra  |  Clinical News

June 3 ASCO Quick Takes: ORR of 32% for Celgene's iberdomide in MM; plus Five Prime, Iovance and more

Celgene highlights iberdomide data for MM at ASCO  Celgene Corp. (NASDAQ:CELG) presented data at ASCO Sunday showing that iberdomide (CC-220) plus dexamethasone led to an overall response rate (ORR) of 32%, including 17 partial responses...
21:58 , Jun 3, 2019 |  BC Extra  |  Clinical News

A tale of two ASCOs: Nektar gains on durability of complete response rate for NKTR-214 combo

After going into ASCO with its valuation roughly half what it was before last year’s meeting kicked off, Nektar gained almost $500 million in market cap on Monday after reporting updated data showing that bempegaldesleukin...
14:09 , Jun 3, 2019 |  BC Extra  |  Clinical News

Astellas, Seattle Genetics ADC could provide new option for checkpoint non-responders in bladder cancer

Data presented at ASCO on Monday for Astellas and Seattle Genetics' enfortumab vedotin showed that metastatic bladder cancer patients who don't respond or relapse after PD-1/PD-L1 therapy could soon have a new treatment option. In...
02:43 , Jun 1, 2019 |  BioCentury  |  Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
21:58 , May 24, 2019 |  BioCentury  |  Product Development

Why quizartinib hiccup at ODAC shouldn’t derail Daiichi’s 2025 cancer drug goals

FDA's ODAC may have given the thumbs down to Daiichi’s quizartinib, but a stocked pipeline and another ongoing trial of the candidate suggest it’s more of a hiccup than a hurdle in the Japanese pharma’s...
22:35 , May 17, 2019 |  BC Extra  |  Clinical News

May 17 Clinical Quick Takes: Achillion Phase III plans for PNH combo; plus NCI, MorphoSys

Achillion to start Phase III of PNH combo in 1H20  Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) said it will start in 1H20 a Phase III trial evaluating oral CFD inhibitor ACH-4471 in combination with C5 inhibitors to...
23:10 , May 16, 2019 |  BC Extra  |  Clinical News

Roche, Bayer unveil brain tumor data for NTRK inhibitors ahead of ASCO

Efficacy data for two tissue-agnostic NTRK inhibitors from Roche and Bayer to treat primary and metastatic brain tumors were released in abstracts ahead of the American Society of Clinical Oncology meeting in Chicago. Data from...